Published in Int J Radiat Oncol Biol Phys on January 01, 2003
Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol (2009) 1.87
(11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging (2006) 1.79
Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume. Radiology (2011) 1.44
Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res (2009) 1.03
Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J Endourol (2008) 0.85
Improving prediction of prostate cancer recurrence using chemical imaging. Sci Rep (2015) 0.82
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med (2007) 10.28
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Incidence and prognosis of syncope. N Engl J Med (2002) 4.69
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med (2006) 4.52
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Magnetic resonance imaging of the breast prior to biopsy. JAMA (2004) 3.97
Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol (2008) 3.92
Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest (2004) 3.90
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology (2012) 3.36
Breast cancer detection based on incremental biochemical and physiological properties of breast cancers: a six-year, two-site study. Acad Radiol (2005) 3.33
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol (2003) 3.21
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res (2006) 3.04
Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. Opt Express (2007) 2.84
MRI-guided diffuse optical spectroscopy of malignant and benign breast lesions. Neoplasia (2002) 2.68
Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology (2006) 2.59
Computerized image-based detection and grading of lymphocytic infiltration in HER2+ breast cancer histopathology. IEEE Trans Biomed Eng (2009) 2.56
Expectation-maximization-driven geodesic active contour with overlap resolution (EMaGACOR): application to lymphocyte segmentation on breast cancer histopathology. IEEE Trans Biomed Eng (2010) 2.52
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer (2014) 2.48
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Comparison of quantitative perfusion imaging using arterial spin labeling at 1.5 and 4.0 Tesla. Magn Reson Med (2002) 2.43
Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy. Photochem Photobiol (2005) 2.33
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac morphogenesis. Proc Natl Acad Sci U S A (2006) 2.28
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology (2007) 2.18
Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology (2007) 2.09
A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients. Urology (2009) 2.06
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
High-throughput detection of prostate cancer in histological sections using probabilistic pairwise Markov models. Med Image Anal (2010) 2.04
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Is ultrasound imaging inferior to computed tomography or magnetic resonance imaging in evaluating renal mass size? Urology (2012) 2.03
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2013) 2.00
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol (2010) 1.99
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics (2008) 1.90
Aortitis and ascending aortic aneurysm: description of 52 cases and proposal of a histologic classification. Hum Pathol (2008) 1.89
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt (2009) 1.82
The burden of depression in prostate cancer. Psychooncology (2011) 1.79
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol (2008) 1.72
Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. Urology (2011) 1.70
Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol (2007) 1.69
Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer (2008) 1.66
Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol (2006) 1.64
PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA (2007) 1.61
A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. Int J Radiat Oncol Biol Phys (2012) 1.61
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer (2014) 1.58
Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol (2011) 1.58
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther (2008) 1.58
Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys (2009) 1.55
Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol (2005) 1.54
What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med (2012) 1.54
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med (2007) 1.53
Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol (2008) 1.52
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol (2011) 1.52
Racial differences in quality of life following prostate cancer diagnosis. Urology (2010) 1.51
Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol (2003) 1.51
Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology (2007) 1.49
Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant (2002) 1.49
Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry (2011) 1.48
Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol (2002) 1.47
Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med (2004) 1.46
Initial clinical experience with contrast-enhanced digital breast tomosynthesis. Acad Radiol (2007) 1.46
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer (2008) 1.46
Incidence of seclusion and restraint in psychiatric hospitals: a literature review and survey of international trends. Soc Psychiatry Psychiatr Epidemiol (2009) 1.44
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Vena caval transection during retroperitoneoscopic nephrectomy: report of the complication and review of the literature. J Urol (2004) 1.43
A multi-institutional study of Internet utilization by radiation oncology patients. Int J Radiat Oncol Biol Phys (2003) 1.43
Factors influencing the length of stay after radical cystectomy: implications for cancer care and perioperative management. Ann Surg Oncol (2014) 1.42
Enucleation of renal cell carcinoma with ablation of the tumour base. BJU Int (2008) 1.41
Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol (2010) 1.41
Atrial endocarditis--the importance of the regurgitant jet lesion. Echocardiography (2005) 1.41
Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int (2014) 1.39